A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7295 Following Single and Multiple Ascending Oral Dose Administration in Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 7295 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors AstraZeneca
- 24 Jul 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 24 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2009 New trial record.